Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H12ClN3O3 |
| Molecular Weight | 305.716 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12[C@H](O)CCN1C(=O)N(C2=O)C3=C(C)C(Cl)=C(C=C3)C#N
InChI
InChIKey=KEJORAMIZFOODM-PWSUYJOCSA-N
InChI=1S/C14H12ClN3O3/c1-7-9(3-2-8(6-16)11(7)15)18-13(20)12-10(19)4-5-17(12)14(18)21/h2-3,10,12,19H,4-5H2,1H3/t10-,12+/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18270691 |
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18270691 |
BMS-564929 is an investigational selective androgen receptor modulator, which is being developed by Bristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men ("andropause"). Bristol-Myers Squibb presented data for BMS 564929 that showed favorable pharmacokinetics and the potential for use at a very low dose (0.03mg).
Originator
Approval Year
Sample Use Guides
Sprague Dawley rats (42–56 d old, 200–250 g) were dosed once daily by oral gavage with BMS-564929 (0.00001–10 mg/kg) in solution/suspension of 80% PEG 400 and 20% Tween 20 for 14 d.
Route of Administration:
Oral
The human cancer epithelial breast cell lines MDA MB-453 and T47D, were used for radioligand competition binding assays. Binding assays were conducted by incubating BMS-564929 at various concentrations with either [3H]DHT or [3H]progesterone with the cells for 2 h at room temperature. BMS-564929 is a high affinity ligand for AR with a Ki of 2.11 ± 0.16 nm
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-BMS-564929
Created by
admin on Fri Dec 15 15:41:22 GMT 2023 , Edited by admin on Fri Dec 15 15:41:22 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
627530-84-1
Created by
admin on Fri Dec 15 15:41:22 GMT 2023 , Edited by admin on Fri Dec 15 15:41:22 GMT 2023
|
PRIMARY | |||
|
9882972
Created by
admin on Fri Dec 15 15:41:22 GMT 2023 , Edited by admin on Fri Dec 15 15:41:22 GMT 2023
|
PRIMARY | |||
|
DB07286
Created by
admin on Fri Dec 15 15:41:22 GMT 2023 , Edited by admin on Fri Dec 15 15:41:22 GMT 2023
|
PRIMARY | |||
|
DTXSID50432357
Created by
admin on Fri Dec 15 15:41:22 GMT 2023 , Edited by admin on Fri Dec 15 15:41:22 GMT 2023
|
PRIMARY | |||
|
9BLW27W4X7
Created by
admin on Fri Dec 15 15:41:22 GMT 2023 , Edited by admin on Fri Dec 15 15:41:22 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
